By the second quarter of 2026, the clinical landscape for aggressive malignancies is being reshaped by the wide availability of complex generic injectables, including liposomal formulations and nanoparticle-bound chemotherapies. These advanced delivery systems, previously restricted by high costs, are now being integrated into standard treatment protocols across Tier 2 and Tier 3 cities. This...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)